advertisement

2 rare Sumatran tigers recovering after catching COVID-19

JAKARTA, Indonesia (AP) - Two rare Sumatran tigers at the zoo in the Indonesian capital are recovering after being infected with COVID-19.

Nine-year-old Tino became ill with shortness of breath, sneezing, and a runny nose on July 9. He also lost his appetite.

Two days later, 12-year-old Hari was showing the same symptoms.

Swabs were taken and results came back positive for COVID-19, Suzi Marsitawati from the Jakarta Parks and Forestry Agency said in a statement on Sunday.

The tigers were immediately treated with antibiotics, antihistamines, anti-inflammatory drugs and multivitamins. They were getting better after 10-12 days, and have now recovered under close observation at Jakarta's Ragunan Zoo.

'œTheir condition is good now. Their appetite has returned and they're being active,'ť Marsitawati said.

Sumatran tigers are the most critically endangered tiger subspecies and are under increasing pressure as their jungle habitat shrinks.

Marsitawati said the Jakarta government is trying to find out how the tigers were infected, because the zoo has been closed as part of coronavirus restrictions. There was no infection among the caretakers and other zoo staff, she said.

Indonesia has become Asia's hot spot with a record number of coronavirus cases in the region.

In this photo released by Jakarta province government, a sumatran tiger who contracting COVID-19 looks out from a cage at the Ragunan Zoo in Jakarta, Indonesia, July 31, 2021. Two rare Sumatran tigers at the zoo in the Indonesian capital are recovering after being infected with COVID-19. (Dadang Kusuma WS/Jakarta Province Government via AP) The Associated Press
Article Comments
Guidelines: Keep it civil and on topic; no profanity, vulgarity, slurs or personal attacks. People who harass others or joke about tragedies will be blocked. If a comment violates these standards or our terms of service, click the "flag" link in the lower-right corner of the comment box. To find our more, read our FAQ.